Morning akinesia and the potential role of gastroparesis - Managing delayed onset of first daily dose of oral levodopa in patients with Parkinson's disease

European Neurological Review

Volumn 8, Issue 2, 2013, Pages 82-84

  Isaacson, Stuart H ^a,b   Chaudhuri, K Ray ^c  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b BOCA RATON REGIONAL HOSPITAL   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Akinesia; Apomorphine; Delayed ON; Gastroparesis; Levodopa; Motor complications; Parkinson's disease

Indexed keywords

EID: 84893078025     PISSN: 17583837     EISSN: 17583845     Source Type: Journal    
DOI: 10.17925/ENR.2013.08.02.82     Document Type: Article

References (46)

1. Rizos A, Kessel B, Martinez-Martin P, et al., Early morning off periods in Parkinson's disease: Characterisation of non motor patterns and treatment effect: An international study [abstract], Mov Disord, 2012;27(Suppl. 1):1582.
2. Chapuis S, Ouchchane L, Metz O, et al., Impact of the motor complications of Parkinson's disease on the quality of life, Mov Disord, 2005;20(2):224-30.
3. Woitalla D, Goetze O, Treatment approaches of gastrointestinal dysfunction in Parkinson's disease, therapeutical options and future perspectives, J Neurol Sci, 2011;310(1-2):152-8.
4. Jost WH, Gastrointestinal dysfunction in Parkinson's Disease, J Neurol Sci, 2010;289(1-2):69-73.
5. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al., The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease, Mov Disord, 2011;26(3):399-406.
6. Doi H, Sakakibara R, Sato M, et al., Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease, J Neurol Sci, 2012;319(1-2):86-8.
7. Jankovic J, Parkinson's disease: clinical features and diagnosis, J Neurol Neurosurg Psychiatry, 2008;79:368-76.
8. Chaudhuri KR, Healy DG, Schapira AH, Non-motor symptoms of Parkinson's disease: diagnosis and management, Lancet Neurol, 2006;5(3):235-45.
9. Kurlan R, Rothfield KP, Woodward WR, et al., Erratic gastric emptying of levodopa may cause 'random' fluctuations of parkinsonian mobility, Neurology,1988;38(3):419-21.
10. Marsden CD, Parkes JD, 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy, Lancet, 1976;1(7954):292-6.
11. Melamed E, Bitton V, Zelig O, Delayed onset of responses to single doses of L-dopa in parkinsonian fluctuators on long-term L-dopa therapy, Clin Neuropharmacol, 1986;9(2):182-8.
12. Stocchi F, Jenner A, Obeso JA, et al., When do levodopa motor fluctuations first appear in Parkinson's disease?, Eur Neurol, 2010;63:257-66.
13. Parkinson Study Group, Pramipexole vs Levodopa as initial treatment for Parkinson Disease. A randomized controlled trial, J Am Med Assoc, 2000;284:1931-8.
14. Wüllner U, Fuchs G, Reketat N, et al., Requirements for Parkinson's disease pharmacotherapy from the patients' perspective: a questionnaire-based survey, Curr Med Res Opin, 2012;28(7):1239-46.
15. Pfeiffer RF, Gastrointestinal dysfunction in Parkinson's disease, Clin Neurosci, 1998;5(2):136-46.
16. Plowman-Prine EK, Sapienza CM, Okun MS, et al., The relationship between quality of life and swallowing in Parkinson's disease, Mov Disord, 2009;15:1352-8.
17. Taylor H, Leitman R, The difficult lives of patients with Parkinson's disease, Health Care News, 2003;3(15).
18. Chaudhuri KR, Martinez-Martin P, Schapira AH, International multicenter pilot study of the first comprehensive self completed non motor symptoms questionnaire for Parkinson's disease: the NMSQuest study, Mov Disord, 2006;21(7):916-23.
19. Edwards LL, Quigley EM, Pfeiffer RF, Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology, Neurology, 1992;42(4):726-32.
20. Jost WH, Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management, Drugs Aging, 1997;10(4):249-58.
21. Valenzuela JE, Defilippi C, Diaz G et al., Effect of dopamine on human gastric and pancreatic secretion, Gastroenterology, 1979;6(2):323-6.
22. Lertxundi U, Peral J, Mora O, et al., Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease, Am J Health Syst Pharm, 2008;65(5):414-19.
23. Djaldetti R, Baron J, Ziv I, et al., Gastric emptying in Parkinson's disease: patients with and without response fluctuations, Neurology, 1996;46(4):1051-4.
24. Comtan prescribing information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/comtan.pdf (accessed 14 January 2014).
25. Tanaka Y, Kato T, Nishida H, et al., Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the 13C-acetate breath test, J Neurol, 2011;258(3):421-6.
26. Heetun ZS, Quigley EM, Gastroparesis and Parkinson's disease: a systematic review, Parkinsonism Relat Disord, 2012;18(5):433-40.
27. Pfeiffer RF, Gastrointestinal dysfunction in Parkinson's disease, Lancet Neurol, 2003;2(2):107-16.
28. Hardoff R, Sula M, Tamir A, et al., Gastric emptying time and gastric motility in patients with Parkinson's disease, Mov Disord, 2001;16(6):1041-7.
29. Nyholm D, Lennernäs H, Irregular gastrointestinal drug absorption in Parkinson's disease, Expert Opin Drug Metab Toxicol, 2008;4(2):193-203.
30. Chaná P, Kuntsmann C, Reyes-Parada M, et al., Delayed early morning turn 'ON' in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be considered, J Neurol Neurosurg Psychiatry, 2004;75(12):1782-3.
31. Müller T, Erdmann C, Bremen D, et al., Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients, Clin Neuropharmacol, 2006;29(2):61-7.
32. Camilleri M, Parkman HP, Shafi MA, et al., Clinical guideline: Management of gastroparesis, Am J Gastroenterol, 2013;108(1):18-38.
33. Arts J, Holvoet L, Caenepeel R, et al., Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis, Aliment Pharmacol Ther, 2007;26:1251-8.
34. Friedenberg FK, Palit A, Parkman HP, et al., Botulinum toxin A for the treatment of delayed gastric emptying, Am J Gastroenterol, 2008;103(2):416-23.
35. Gil RA, Hwynn N, Fabian T, et al., Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients, Parkinsonism Relat Disord, 2011;17(4):285-7.
36. O'Grady G, Egbuji JU, Du P, et al., High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis, World J Surg, 2009;33(8):1693-701.
37. Sujith OK, Lane C, Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease, Ther Adv Neurolog Disord, 2009;2(2):105-13.
38. Jansen EN, Meerwaldt JD, Madopar HBS in Parkinson patients with nocturnal akinesia, Clin Neurol Neurosurg, 1988;90(1):35-9.
39. Ondo WG, Shinawi L, Moore S, Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, doubledummy, placebo-controlled, crossover trial, Mov Disord, 2010;25(16):2724-7.
40. Müller T, Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopaassociated motor complications, Clin Neuropharmacol, 2013;36(3):84-91.
41. Trenkwalder C, Kies B, Rudzinska M, et al., Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER), Mov Disord, 2011;26(1):90-99.
42. Giladi N, Fichtner A, Poewe W, et al., Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease, J Neural Transm, 2010;117(12):1395-9.
43. Stocchi F, Rabey JM, Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease, Eur J Neurol, 2011;18(12):1373-8.
44. Elmer LW, Rasagiline adjunct therapy in patients with Parkinson's disease: Post hoc analyses of the PRESTO and LARGO trials, Parkinsonism Relat Disord, 2013;19(11):930-36.
45. Trosch RM, Silver D, Bottini PB, Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease. A 6-month open-label study, CNS Drugs, 2008;22(6):519-27.
46. Pfeiffer RF, Gutmann L, Hull KL Jr, et al., Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease, Parkinsonism Relat Disord, 2007;13(2):93-100.